Terms: = Bone cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
82 results:
1. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
Bauer M; Jäkel N; Wilfer A; Haak A; Eszlinger M; Kelemen K; Haemmerle M; Al-Ali HK; Seliger B; Wickenhauser C
Oncoimmunology; 2024; 13(1):2323212. PubMed ID: 38481730
[TBL] [Abstract] [Full Text] [Related]
3. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-pd-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
4. Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.
Cheng D; Zhang Z; Liu D; Mi Z; Tao W; Fu J; Fan H
Cancer Immunol Immunother; 2024 Jan; 73(2):35. PubMed ID: 38280005
[TBL] [Abstract] [Full Text] [Related]
5. Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.
Ding M; Ran X; Qian S; Zhang Y; Wang Z; Dong M; Yang Z; Wu S; Feng X; Zhang J; Zhu L; Niu S; Zhang X
Aging (Albany NY); 2023 Dec; 15(24):15360-15381. PubMed ID: 38180104
[TBL] [Abstract] [Full Text] [Related]
6. Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.
Wang N; Wang L; Huang A; Han J; Cao T; Mei X; Yao J; Xiao Y; Ma H
Front Immunol; 2023; 14():1273962. PubMed ID: 38162668
[TBL] [Abstract] [Full Text] [Related]
7. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
Shi M; Sun D; Ma X; Liu J; Zhang Y; Liu T; Chen X; Mo S; Zhao Y; Zhang L
Hum Vaccin Immunother; 2023 Dec; 19(3):2294579. PubMed ID: 38111107
[TBL] [Abstract] [Full Text] [Related]
8. Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia.
Peng Q; Huang R; Wang H; Xiao H; Wang Y; Zhai Z; Wang Z
Cancer Immunol Immunother; 2023 Dec; 72(12):4399-4414. PubMed ID: 37932426
[TBL] [Abstract] [Full Text] [Related]
9. Association of the m
Li Y; Cao J; Wang J; Wu W; Jiang L; Sun X
Cancer; 2024 Feb; 130(3):356-374. PubMed ID: 37861451
[TBL] [Abstract] [Full Text] [Related]
10. Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade.
Gorgulho J; Roderburg C; Beier F; Bokemeyer C; Brümmendorf TH; Luedde T; Loosen SH
Front Immunol; 2023; 14():1206953. PubMed ID: 37705980
[TBL] [Abstract] [Full Text] [Related]
11. A novel stratification framework based on anoikis-related genes for predicting the prognosis in patients with osteosarcoma.
Zhang X; Wen Z; Wang Q; Ren L; Zhao S
Front Immunol; 2023; 14():1199869. PubMed ID: 37575253
[TBL] [Abstract] [Full Text] [Related]
12. Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.
Rutkowski P; Czarnecka AM
Expert Rev Anticancer Ther; 2023; 23(9):897-902. PubMed ID: 37573515
[TBL] [Abstract] [Full Text] [Related]
13. Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.
Bhasin SS; Thomas BE; Summers RJ; Sarkar D; Mumme H; Pilcher W; Emam M; Raikar SS; Park SI; Castellino SM; Graham DK; Bhasin MK; DeRyckere D
Sci Rep; 2023 Aug; 13(1):12556. PubMed ID: 37532715
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract] [Full Text] [Related]
15. Osteosarcoma-Associated Immune Genes as Potential Immunotherapy and prognosis Biomarkers.
Yang L; Long Y; Xiao S
Biochem Genet; 2024 Apr; 62(2):798-813. PubMed ID: 37452172
[TBL] [Abstract] [Full Text] [Related]
16. Neoadjuvant pd-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract] [Full Text] [Related]
17. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Merrill MH; Dahi PB; Redd RA; McDonough MM; Chen YB; DeFilipp Z; Herrera AF; Fisher DC; LaCasce AS; Odejide OO; Ng SY; Jacobson CA; Merryman RW; Kim AI; Nieto YL; Sauter CS; Shah GL; Zain JM; Armand P; Jacobsen ED
Blood; 2023 Aug; 142(7):621-628. PubMed ID: 37319432
[TBL] [Abstract] [Full Text] [Related]
18. Immunological role and prognostic value of the SKA family in pan-cancer analysis.
Li Z; Huang L; Li J; Yang W; Li W; Long Q; Dai X; Wang H; Du G
Front Immunol; 2023; 14():1012999. PubMed ID: 37180139
[TBL] [Abstract] [Full Text] [Related]
19. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
[TBL] [Abstract] [Full Text] [Related]
20. Predictive value of
Tang S; Zhang Y; Li Y; Zhang Y; Xu Y; Ding H; Chen Y; Ren P; Ye H; Fu S; Lin S
Front Immunol; 2023; 14():1034416. PubMed ID: 36860861
[TBL] [Abstract] [Full Text] [Related]
[Next]
